Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Daphne Ayton, B.A.
- Phone Number: 832-206-4034
- Email: daphne.ayton@bcm.edu
Study Contact Backup
- Name: Eric Storch, Ph.D.
- Phone Number: (713) 798-3579
- Email: eric.storch@bcm.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor College of Medicine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- The child is between the ages of 7 to 13 years inclusion at enrollment
- The child has clinically significant symptoms of anxiety and/or OCD, as indicated by a score of 12 or higher on the Pediatric Anxiety Rating Scale (PARS).
- The child is appropriate for anxiety-focused treatment (e.g., anxiety is the primary or co-primary problem as diagnosed using the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID).
- One parent/guardian is able and willing to participate in assessment and treatment (e.g., has sufficient English fluency, the decisional capacity to participate, and can commit to treatment duration).
- The participating parent/guardian lives with their child at least 50% of the time per self-report.
- Both parent and child are able to read and understand English.
- The child has the intellectual and communication skills to engage in CBT, as judged by an experienced supervising clinician.
- Participants must be in the state of Texas for treatment sessions/assessments.
Exclusion Criteria:
- the child has a diagnosis of child lifetime bipolar disorder, drug or alcohol dependence, psychotic disorder, or conduct disorder.
- the child has severe, current suicidal/homicidal ideation and/or self-injury requiring medical intervention (referrals will be made for appropriate clinical intervention).
- the child is receiving concurrent therapy for anxiety.
- New Treatments: Initiation of an antidepressant within 12 weeks before study enrollment OR 6 weeks for an antipsychotic, benzodiazepine, or attention deficit hyperactivity disorder (ADHD) medication before study enrollment. Established Treatment changes: Any change in established psychotropic medication (e.g., antidepressants, anxiolytics, antipsychotic) within 4 weeks before study enrollment. Any medications must remain stable during treatment; downward adjustments due to side effects may be acceptable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Family-Based Internet-Based CBT Group (iCBT)
One third of participants will be randomized to receive iCBT.
Each week of treatment, the parent will be encouraged to read the corresponding materials on the Baylor College of Medicine (BCM) webpage, complete accompanying worksheets, and guide their child through completing activities in the child-facing materials, with support from a therapist (6 30-minute supportive videoconferencing via Zoom, 6 emails on alternating weeks).
One core aspect of treatment will be parents leading their child through graduated exposure.
Exposures, a hallmark of CBT for anxiety, are used to gradually and repeatedly confront feared stimuli.
For example, exposure therapy for a child fearful of dogs may begin with looking at pictures of dogs and standing across the park from a dog on a leash, to eventually petting a dog.
All relevant information regarding parent-led exposures will be detailed in the treatment materials, and therapists will review with parents via email and/or video-conferencing sessions.
|
Family-based cognitive behavioral therapy employing internet-delivered modules and videos
|
|
Experimental: Parent Training Bibliotherapy (SPACE)
One third of participants will be randomized to the SPACE group.
Families will receive 4 45-minute supportive video calls with a therapist over the course of 12-14 weeks.
Participating families will receive a copy of the book 'Breaking Free of Child Anxiety and OCD' to use at home and in session with the therapist.
During each of the video-conferencing sessions, therapists will serve to provide encouragement and support as the parent works through the program independently.
|
Parent-based bibliotherapy for treating anxiety disorders in youth
|
|
Active Comparator: Active Comparator
One third of participants will be randomized to receive a Relaxation and Mentorship.
This involves attending 4 45-minute sessions with a therapist over the course of 12-14 weeks.
Topics covered include breathing slowly and deeply, coloring activities, and releasing muscle tension to reduce stress levels.
|
Relaxation based treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in clinician-rated child anxiety severity throughout the past week.
Time Frame: baseline (before treatment), during treatment (on average 14 weeks), post-treatment (last week of treatment), 1 month follow up
|
Each item is scored on a 0 to 5 scale (higher scores correspond to greater severity), yielding a total between 0 and 30.
|
baseline (before treatment), during treatment (on average 14 weeks), post-treatment (last week of treatment), 1 month follow up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anxiety Disorders Interview Schedule (ADIS-IV) with Clinical Severity Ratings
Time Frame: baseline (before treatment), during treatment (on average 14 weeks), post-treatment (last week of treatment), 1 month follow up
|
Clinician-rated diagnostic interview that includes current anxiety disorders, depression, obsessive-compulsive disorder, and related disorders.
Each diagnostic category is coded as present or absent based on symptom criteria and clinical severity ratings (CSRs), which indicate the level of clinical interference.
CSRs are scored on a 0-8 scale (0 = not at all; 8 = very, very much).
CSRs of 4 or above indicate the clinical levels.
|
baseline (before treatment), during treatment (on average 14 weeks), post-treatment (last week of treatment), 1 month follow up
|
|
Clinical Global Impression-Severity
Time Frame: baseline (before treatment), during treatment (on average 14 weeks), post-treatment (last week of treatment), 1 month follow up
|
Clinician-rated child psychopathology severity rating.
A single item is scored 0-6 (0= no illness; 6= extremely severe symptoms).
|
baseline (before treatment), during treatment (on average 14 weeks), post-treatment (last week of treatment), 1 month follow up
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Neurodevelopmental Disorders
- Anxiety Disorders
- Obsessive-Compulsive Disorder
- Panic Disorder
- Anxiety, Separation
- Generalized Anxiety Disorder
- Therapeutics
- Patient Care
- Psychotherapy
- Behavioral Disciplines and Activities
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Bibliotherapy
Other Study ID Numbers
Other Study ID Numbers
- H-53969
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Anxiety Disorder
-
NCT07430800RecruitingGeneralized Anxiety Disorder (GAD)
-
NCT07391020RecruitingAnxiety | Generalized Anxiety Disorder (GAD) | Worrying
-
NCT07123467RecruitingAnxiety Disorders | Generalized Anxiety Disorder (GAD)
-
NCT06846320Recruiting
-
NCT07239609RecruitingGrief | Anxiety Disorder Generalized | Depression in Adults
-
NCT07225192Not yet recruitingMajor Depressive Disorder | Generalized Anxiety Disorder (GAD)
-
NCT07620340Not yet recruitingMajor Depressive Disorder (MDD) | Generalized Anxiety Disorder (GAD)
-
NCT07177365Not yet recruitingMajor Depressive Disorder (MDD) | Generalized Anxiety Disorder (GAD)
-
NCT07477990Recruiting
-
NCT07483918CompletedSubstance Use Disorder (SUD) | Anxiety Disorder Generalized
Clinical Trials on Family Based, Internet-Based Cognitive Behavioral Therapy
-
NCT07024758RecruitingPanic Disorder | Separation Anxiety Disorder | Anxiety Disorder of Childhood or Adolescence | Obsessive Compulsive Disorder (OCD) | Panic Attacks | Social Anxiety Disorder of Childhood | Phobia, Specific | Generalized Anxiety Disorder (GAD) | Panic Disorder (With or Without Agoraphobia)
-
NCT02541968CompletedObsessive-compulsive Disorder
-
NCT02519569UnknownComplicated Grief
-
NCT05700539Recruiting
-
NCT05413941WithdrawnInflammatory Bowel Diseases | Psychological Distress
-
NCT02091765CompletedSexual Dysfunction | Breast Cancer Survivors | Intimacy Problems
-
NCT05656430CompletedAnxiety Symptoms | Depression Symptoms
-
NCT02588079Completed
-
NCT05673382Active, not recruitingDepressive Symptoms | Anxiety Symptoms
-
NCT07373405Not yet recruitingAlcohol Use Disorder (AUD)